Novartis Ag

Lee Edwards

Catherine Howsham

Emma Budd

Kamlesh Jagdis Bala

Nichola Smith

Peter Hunt

Gurdip Bhalay

Katrin Spiegel

Glyn Alan Hughes

Stephen Paul Collingwood

Urs Baettig

Graham Charles Bloomfield

Darren Mark LeGrand

Paul Joseph Oakley

Thomas Anthony Hunt

Andrew Dunstan

Peter Gedeck

Ian Bruce

Darren Mark Legrand

Roger John Taylor

Timothy John Ritchie

Andrew James Culshaw

Christopher Thomas Brain

Brian Cox

Darren Mark Le Grand

Edward Charles Hall

Terance William Hart

Judy Fox Hayler

Edward Karol Dziadulewicz

Rebecca Butler

Paul Oakley

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Pyridine and pyrazine derivative for the treatment of chronic bronchitis

Pyridine and pyrazine derivative for the treatment of CF

A compound of Formula I in free or salt or solvate form, where R, R, R, R, R, R, R, R, R, Rand Rhave the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, R, R, R, R, and Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Pyrazine derivatives as ENaC blockers

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

N-substituted heterocyclyl carboxamides

The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. 

Heterocyclic compounds for the treatment of CF

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R-Rand Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R, R, Ar', A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.

Pyrazine compounds as PI3 kinase inhibitors

Pyrazine derivatives as enac blockers

Growing community of inventors

Horsham, United Kingdom

Lee Edwards